Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
11.39
-0.04 (-0.35%)
At close: Jun 26, 2026, 4:00 PM EDT
11.17
-0.22 (-1.93%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 131 employees as of December 31, 2025. The number of employees increased by 35 or 36.46% compared to the previous year.
Employees
131
Change (1Y)
35
Growth (1Y)
36.46%
Revenue / Employee
n/a
Profits / Employee
-$1,351,467
Market Cap
994.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| MeiraGTx Holdings | 409 |
| Pharming Group | 407 |
| Kura Oncology | 260 |
| DBV Technologies | 161 |
| Sana Biotechnology | 142 |
| Alpha Tau Medical | 121 |
| ORIC Pharmaceuticals | 104 |
OLMA News
- 18 days ago - Olema Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Olema Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Olema Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 4 weeks ago - Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 5 weeks ago - Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - GlobeNewsWire
- 5 weeks ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology - TheFly